title: Authors' Reply: Is Genotype Testing Really Cost-Effective for Primary Resistance in Brazil?
authors.affiliation: *Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil †Yale School of Public Health, New Haven, CT.
authors.forename: Paula M
authors.initials: PM
authors.lastname: Luz
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Valdilea G
authors.initials: VG
authors.lastname: Veloso
authors.forename: A David
authors.initials: AD
authors.lastname: Paltiel
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005260:Female; D060005:Genotyping Techniques / Q000191:economics* / Q000379:methods*; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D008297:Male
chemical_list: D044966:Anti-Retroviral Agents